Shelley Allen
Director - Project & Peptide Discovery Abbvie
Shelley Allen is an accomplished drug discovery leader with more than 25 years of experience in medicinal chemistry. She has a proven history of building and leading successful teams in both biotech and pharma, consistently delivering high-quality drug candidates with a strong sense of urgency. Shelley served as the Head of Drug Discovery at Nimble Therapeutics until its acquisition by AbbVie earlier this year. She now continues her impactful work at AbbVie, contributing to the discovery and development of peptide programs within the Immuno-Pharmacology & Peptide Discovery group.
Seminars
Thursday 30th April 2026
Roundtable Discussion: From Discovery to Translation; Developing Cell Permeable & Orally Bioavailable Peptides with Optimal Pharmacology & DMPK
2:30 pm
- Modifying amino acids to optimise target selectivity and cell membrane permeability to achieve the right pharmacology
- Modelling protein-protein interactions in the discovery to translate into the preclinical setting
- Analysing the pharmacokinetic and biodistribution properties of highly soluble orally bioavailable peptides to ensure efficacy when entering the clinic
